Insider Trading Activity aTyr Pharma Inc (NASDAQ:LIFE) – CEO Bought 2,552 shares of Stock

20

Insider Trading Activity For aTyr Pharma Inc (NASDAQ:LIFE)

John Mendlein , CEO of aTyr Pharma Inc (NASDAQ:LIFE) reportedly Bought 2,552 shares of the company’s stock at an average price of 3 for a total transaction amount of $7,656.00 SEC Form

Insider Trading History For aTyr Pharma Inc (NASDAQ:LIFE)

  • On 5/28/2013 John A Cottingham, Insider, sold 60,000 with an average share price of $74.03 per share and the total transaction amounting to $4,441,800.00. View SEC Filing
  • On 5/29/2013 David C Uprichard, Director, sold 2,010 with an average share price of $74.04 per share and the total transaction amounting to $148,820.40. View SEC Filing
  • On 5/12/2015 Sofinnova Venture Partners Ix,, Major Shareholder, bought 320,000 with an average share price of $14.00 per share and the total transaction amounting to $4,480,000.00. View SEC Filing
  • On 5/12/2015 James E Flynn, Insider, bought 50,000 with an average share price of $14.00 per share and the total transaction amounting to $700,000.00. View SEC Filing
  • On 4/5/2016 Paul Schimmel, Director, bought 25,000 with an average share price of $3.52 per share and the total transaction amounting to $88,000.00. View SEC Filing
  • On 4/5/2016 John Mendlein, CEO, bought 2,500 with an average share price of $3.55 per share and the total transaction amounting to $8,875.00. View SEC Filing
  • On 4/6/2016 Paul Schimmel, Director, bought 25,000 with an average share price of $3.20 per share and the total transaction amounting to $80,000.00. View SEC Filing
  • Analyst Ratings For aTyr Pharma Inc (NASDAQ:LIFE)
    These are 3 Hold Ratings .
    The current consensus rating for aTyr Pharma Inc (NASDAQ:LIFE) is Hold (Score: 2.00) with a consensus target price of $3.62 , a potential (18.58% upside)

    Analyst Ratings History For aTyr Pharma Inc (NASDAQ:LIFE)

    • On 3/31/2016 William Blair Downgraded rating Outperform to Market Perform
    • On 3/18/2017 JPMorgan Chase & Co. Reiterated Rating Hold
    • On 3/18/2017 BMO Capital Markets Set Price Target of rating Hold with a price target of $4.00
    • On 3/20/2017 Citigroup Inc Boost Price Target of rating Neutral with a price target of $3.00 to $4.00

    About aTyr Pharma Inc (NASDAQ:LIFE)
    aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

    Recent Trading Activity for aTyr Pharma Inc (NASDAQ:LIFE)
    Shares of aTyr Pharma Inc closed the previous trading session at 3.05 up +0.02 0.83% with 36,248 shares trading hands.

    An ad to help with our costs